Acute and long-term gastrointestinal consequences of chemotherapy
F Di Fiore, E Van Cutsem - Best Practice & Research Clinical …, 2009 - Elsevier
There are many anti-neoplastic agents in cancer treatment. Combination regimens are often
the main standard treatment, particularly for gastrointestinal malignancies. The introduction
of new regimens that combine fluoropyrimidines with irinotecan or oxaliplatin and recently
also with antibodies against the Epidermal Growth Factor Receptor (EGFR)(cetuximab and
panitumumab) and against the Vascular Endothelial Growth Factor (VEGF)(bevacizumab)
pathways, has dramatically improved the progression free survival and survival of patients …
the main standard treatment, particularly for gastrointestinal malignancies. The introduction
of new regimens that combine fluoropyrimidines with irinotecan or oxaliplatin and recently
also with antibodies against the Epidermal Growth Factor Receptor (EGFR)(cetuximab and
panitumumab) and against the Vascular Endothelial Growth Factor (VEGF)(bevacizumab)
pathways, has dramatically improved the progression free survival and survival of patients …
